Literature DB >> 10691999

Expression of keratinocyte growth factor and its receptor in colorectal cancer.

J M Otte1, F Schmitz, T Banasiewicz, M Drews, U R Fölsch, K H Herzig.   

Abstract

BACKGROUND AND AIMS: The mesenchymal derived keratinocyte growth factor stimulates growth, differentiation and migration of intestinal epithelial cells. In the human gastrointestinal tract an overexpression of this growth factor has been reported in inflammatory bowel disease and pancreatic cancer. In the present study we investigated expression patterns of keratinocyte growth factor and receptor in normal and neoplastic colonic mucosa and in metastases. Furthermore, biological effects on normal intestinal and colorectal cancer cell lines were determined.
MATERIALS AND METHODS: Expression patterns were analysed at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level by Western blotting. Localization of ligand and receptor in normal intestinal mucosa and cancer tissue was investigated by immunohistochemistry. Mitogenic effects of keratinocyte growth factor were assayed by [3H]thymidine incorporation in normal (Intestine-407, IEC-6, IEC-18) and colorectal cancer cell lines (Colo320, LoVo, SW403, SW707).
RESULTS: mRNA expression of keratinocyte growth factor and receptor was detected in the majority of normal and cancer samples without significant alterations. At the protein level keratinocyte growth factor expression did not differ between normal and malignant specimens, whereas protein expression of the receptor was increased up to twofold in well- to moderately differentiated colorectal cancers. DNA synthesis was significantly stimulated by keratinocyte growth factor in all three normal intestinal cell lines, whereas this growth factor did not significantly alter the [3H]thymidine incorporation in the colorectal cancer cell lines.
CONCLUSION: Keratinocyte growth factor and its receptor were detected in the majority of samples from normal and neoplastic colonic mucosa, with an overexpression of the receptor seen in the more differentiated tumour samples. Keratinocyte growth factor is a strong mitogen for normal intestinal cells, whereas it is less effective in neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691999     DOI: 10.1046/j.1365-2362.2000.00617.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APC(Min/+) mice.

Authors:  Gopal Pathuri; Qian Li; Altaf Mohammed; Hariprasad Gali; J Thomas Pento; Chinthalapally V Rao
Journal:  Bioorg Med Chem Lett       Date:  2014-01-27       Impact factor: 2.823

2.  Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation.

Authors:  Abhilasha Patel; Gyanendra Tripathi; Philip McTernan; Kishore Gopalakrishnan; Omar Ali; Emma Spector; Nigel Williams; Ramesh P Arasaradnam
Journal:  J Gastrointest Oncol       Date:  2019-06

3.  Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.

Authors:  Yoko Matsuda; Junji Ueda; Toshiyuki Ishiwata
Journal:  Patholog Res Int       Date:  2012-06-04

4.  Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Authors:  Andrew Woolston; Khurum Khan; Georgia Spain; Louise J Barber; Beatrice Griffiths; Reyes Gonzalez-Exposito; Lisa Hornsteiner; Marco Punta; Yatish Patil; Alice Newey; Sonia Mansukhani; Matthew N Davies; Andrew Furness; Francesco Sclafani; Clare Peckitt; Mirta Jiménez; Kyriakos Kouvelakis; Romana Ranftl; Ruwaida Begum; Isma Rana; Janet Thomas; Annette Bryant; Sergio Quezada; Andrew Wotherspoon; Nasir Khan; Nikolaos Fotiadis; Teresa Marafioti; Thomas Powles; Stefano Lise; Fernando Calvo; Sebastian Guettler; Katharina von Loga; Sheela Rao; David Watkins; Naureen Starling; Ian Chau; Anguraj Sadanandam; David Cunningham; Marco Gerlinger
Journal:  Cancer Cell       Date:  2019-07-08       Impact factor: 31.743

5.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Authors:  Anita L Bane; Dushanthi Pinnaduwage; Sarah Colby; Michael Reedijk; Sean E Egan; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

6.  In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.

Authors:  Maud Verstraete; Annelies Debucquoy; Annelies Gonnissen; Ruveyda Dok; Sofie Isebaert; Ellen Devos; William McBride; Karin Haustermans
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.